» Articles » PMID: 39858015

Molecular Insights on Signaling Cascades in Breast Cancer: A Comprehensive Review

Abstract

The complex signaling network within the breast tumor microenvironment is crucial for its growth, metastasis, angiogenesis, therapy escape, stem cell maintenance, and immunomodulation. An array of secretory factors and their receptors activate downstream signaling cascades regulating breast cancer progression and metastasis. Among various signaling pathways, the EGFR, ER, Notch, and Hedgehog signaling pathways have recently been identified as crucial in terms of breast cancer proliferation, survival, differentiation, maintenance of CSCs, and therapy failure. These receptors mediate various downstream signaling pathways such as MAPK, including MEK/ERK signaling pathways that promote common pro-oncogenic signaling, whereas dysregulation of PI3K/Akt, Wnt/β-catenin, and JAK/STAT activates key oncogenic events such as drug resistance, CSC enrichment, and metabolic reprogramming. Additionally, these cascades orchestrate an intricate interplay between stromal cells, immune cells, and tumor cells. Metabolic reprogramming and adaptations contribute to aggressive breast cancer and are unresponsive to therapy. Herein, recent insights into the novel signaling pathways operating within the breast TME that aid in their advancement are emphasized and current developments in practices targeting the breast TME to enhance treatment efficacy are reviewed.

Citing Articles

Cancer Risk in IBD Patients Treated with JAK Inhibitors: Reassuring Evidence from Trials and Real-World Data.

Puca P, Del Gaudio A, Iaccarino J, Blasi V, Coppola G, Laterza L Cancers (Basel). 2025; 17(5).

PMID: 40075582 PMC: 11899451. DOI: 10.3390/cancers17050735.

References
1.
Nolan E, Lindeman G, Visvader J . Deciphering breast cancer: from biology to the clinic. Cell. 2023; 186(8):1708-1728. DOI: 10.1016/j.cell.2023.01.040. View

2.
Royce M, Bachelot T, Villanueva C, Ozguroglu M, Azevedo S, Cruz F . Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical Trial. JAMA Oncol. 2018; 4(7):977-984. PMC: 5885212. DOI: 10.1001/jamaoncol.2018.0060. View

3.
Kim H, Koo J . The Role of Autophagy in Breast Cancer Metastasis. Biomedicines. 2023; 11(2). PMC: 9953203. DOI: 10.3390/biomedicines11020618. View

4.
Comin-Anduix B, Escuin-Ordinas H, Ibarrondo F . Tremelimumab: research and clinical development. Onco Targets Ther. 2016; 9:1767-76. PMC: 4809326. DOI: 10.2147/OTT.S65802. View

5.
Emens L, Esteva F, Beresford M, Saura C, De Laurentiis M, Kim S . Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020; 21(10):1283-1295. DOI: 10.1016/S1470-2045(20)30465-4. View